Get the Stockscreener App
6.14
1.06%
0.025
Transcode Therapeutics Inc stock is traded at $6.14, with a volume of 4,357.
It is up +1.06% in the last 24 hours and down -28.12% over the past month.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
See More
Previous Close:
$6.115
Open:
$6.04
24h Volume:
4,357
Relative Volume:
0.44
Market Cap:
$5.83M
Revenue:
-
Net Income/Loss:
$-34.66M
P/E Ratio:
-0.063
EPS:
-97.5284
Net Cash Flow:
$-19.52M
1W Performance:
-6.36%
1M Performance:
-28.12%
6M Performance:
-28.47%
1Y Performance:
-18.90%
1-Day Range:
$6.04
$6.55
1-Week Range:
$5.5598
$7.14
52-Week Range:
$5.5598
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
6.14 | 5.81M | 0 | -34.66M | -19.52M | -97.53 |
VRTX
Vertex Pharmaceuticals Inc
|
434.00 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.18 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.63 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.49 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.81 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
[EFFECT] Transcode Therapeutics, Inc. SEC Filing - Stock Titan
What TransCode Therapeutics RNAZ flagged as biggest challenges ahead Q4 2024 Below ExpectationsQuarterly Earnings - newser.com
TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] Transcode Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
Mesa Air Group, Inc.Common Stock (NQ: MESA - FinancialContent
What you need to know before buying TransCode Therapeutics (RNAZ) (Breakdown Watch) 2026-05-11Fast Rising Picks - newser.com
What TransCode Therapeutics (RNAZ) flagged as biggest challenges ahead | Q4 2024: Below ExpectationsHigh Interest Stocks - newser.com
Trading Systems Reacting to (RNAZ) Volatility - Stock Traders Daily
TransCode Therapeutics (RNAZ) asks shareholders to OK preferred conversions, SEPA funding - Stock Titan
How TransCode Therapeutics (RNAZ) differentiates itself from competitors (Near Highs) 2026-05-08Open Stock Signal Network - newser.com
TransCode Therapeutics 2025 10-K/A: Executive Compensation, Board Members, and Corporate Governance Overview - Minichart
TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) updates 2025 governance, executive pay and ownership - Stock Titan
MSN Money - MSN
TransCode Therapeutics (NASDAQ: RNAZ) sets up 1.53M-share SEPA resale - Stock Titan
TransCode names Anna Moore scientific board chair - Investing.com UK
TransCode Therapeutics Appoints Dr. Anna Moore as Scientific Advisory Board Chair, Signs Research Agreement with Michigan State University - citybuzz -
TransCode names Anna Moore scientific board chair By Investing.com - Investing.com Australia
Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board - marketscreener.com
TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University - PR Newswire
RNAZ News | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill
TransCode Therapeutics signs financing deal worth up to $20 million - MSN
RNAZ (TransCode Therapeutics Inc.) posts far wider than expected Q4 2024 loss, shares notch small gain in today’s trading.Asset Sale - Xã Thanh Hà
TransCode Therapeutics (RNAZ) Stock: Volatility Overview (-4.45%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
YA II affiliates report 101,772 shares in TransCode Therapeutics (RNAZ) under convertible note - Stock Titan
(RNAZ) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TransCode Therapeutics 2025 10-K: Advancing RNA and Immuno-Oncology Cancer Therapeutics with Proprietary TTX Platform - Minichart
TransCode Therapeutics (RNAZ) Stock Dual Listing (Smart Money Flows) 2026-04-15Verified Signals - Xã Thanh Hà
TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TransCode Therapeutics (NASDAQ: RNAZ) expands cancer pipeline with Polynoma and Unleash deals - Stock Titan
TransCode Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Weekly: Is TransCode Therapeutics Inc showing insider buying2026 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Geopolitics Watch: Can TransCode Therapeutics Inc sustain its profitability - baoquankhu1.vn
Chipmakers Recap: Is TransCode Therapeutics Inc a good stock for dollar cost averaging2026 Macro Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Big Picture: What is TransCode Therapeutics Incs P E ratio telling us2026 Earnings & Real-Time Buy Signal Alerts - baoquankhu1.vn
Insider Sell: Why is TransCode Therapeutics Inc stock going downEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
TransCode Therapeutics Secures New Financing to Extend Runway - The Globe and Mail
TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - Bitget
TransCode Therapeutics Secures Up to $20 Million Financing for Metastatic Cancer Trial - citybuzz -
TransCode Therapeutics Secures Up to $20 Million Flexible Financing to Advance Lead Cancer Program and Extend Runway Into 2028 - Minichart
Eightco (NASDAQ: ORBS) Represents the Biggest Public Market Exposure to OpenAI for Retail Investors - Weekly Voice
TransCode Therapeutics Secures $20M Financing - citybiz
Transcode Therapeutics Secures Up To $14 Million Standby Equity Facility and $6 Million Notes With Yorkville - TradingView — Track All Markets
TransCode Therapeutics (NASDAQ: RNAZ) lines up up to $20M in new flexible funding - Stock Titan
TransCode lands $20M to keep its cancer trial funded into 2027 - Stock Titan
Market Overview: How sensitive is TransCode Therapeutics Inc to inflationWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Form 8-KCurrent report - ADVFN
Responsive Playbooks and the RNAZ Inflection - Stock Traders Daily
RNAZ PE Ratio & Valuation, Is RNAZ Overvalued - Intellectia AI
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.06%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):